News & Press

Lamellar Biomedical Ltd is pleased to provide you with news and information on the Company and its areas of interest:

Press release: 7 January 2013

Lamellar Biomedical raises £3.3 million from Instituational investors

Lamellar Biomedical is pleased to announce that it has raised £3.3 million in equity financing from existing and new

shareholders including Barwell, Scottish Enterprise and TRI Cap angel investors. Funds managed by Invesco Perpetual

form the core of the new shareholding.

_______________________________________________________________________________________________

Press release: 16 June 2011

Lamellar Biomedical Secures its First Orphan Drug Licence

Provides 10-year Market Exclusivity for the treatment of Cystic Fibrosis

Glasgow biopharmaceutical firm, Lamellar Biomedical Ltd, launched four years ago to develop a new class of therapies for the prevention, treatment and control of severe respiratory disease, today announced that their lead clinical candidate LMS-611 for the treatment of patients with cystic fibrosis has ... more>>

Press release: 18-21 May 2009

Lamellar Biomedical took its science and Lamellasomes abroad to the BIO International Convention, Philadelphia, USA

Press release: 12-14 October 2008

Lamellar Biomedical made a podium presentation at the 2008 BioPartnering Europe conference in London, UK

Press release: 18 September 18 2008

Young Company Finance invited Lamellar Biomedical Ltd to present at their annual conference in Stirling, UK

Press release: 17 September 2007

Investors Group Pumps 1m Into Lamellar Biomedical (from The Herald)

A Bellshill-based firm, which is planning to pioneer a new treatment for cystic fibrosis and other respiratory diseases, has received a funding boost of nearly £1m from a consortium of investors, instigated by... more>>

For further information please contact Lamellar Biomedical
Tel: +44 (0) 1698 748832 Fax: +44 (0) 1698 849500 Email: info@lamellar.com